Tiziana Life Sciences Ltd (TLSA)

Overview News Price History Option Chain Discussions Forecast Stock Split

Tiziana Life Sciences Ltd stock is currently priced at $0.666, with a 24-hour trading volume of 602.37K. It has seen a +4.06% increased in the last 24 hours and a +35.92% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.65 pivot point. If it approaches the $0.81 resistance level, significant changes may occur.

Tiziana Life Sciences Ltd Stock (TLSA) Financials Data

Tiziana Life Sciences Ltd (TLSA) Net Income 2024

TLSA net income (TTM) was -$19.50 million for the quarter ending June 30, 2023, a +49.09% increase year-over-year.

Tiziana Life Sciences Ltd (TLSA) Cash Flow 2024

TLSA recorded a free cash flow (TTM) of -$19.09 million for the quarter ending June 30, 2023, a -7.58% decrease year-over-year.

Tiziana Life Sciences Ltd (TLSA) Earnings per Share 2024

TLSA earnings per share (TTM) was -$0.182 for the quarter ending June 30, 2023, a +58.35% growth year-over-year.

Tiziana Life Sciences Ltd Stock (TLSA) Latest News

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

GlobeNewswire Inc.

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

GlobeNewswire Inc.

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

GlobeNewswire Inc.

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease

GlobeNewswire Inc.

Buy Tesla Stock for Humanoid Robots and Full-Self Driving?

Zacks Investment Research

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

GlobeNewswire Inc.

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.